Literature DB >> 19542448

Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.

Petra Riedl1, Andreas Wieland, Kasper Lamberth, Soren Buus, Francois Lemonnier, Kurt Reifenberg, Jörg Reimann, Reinhold Schirmbeck.   

Abstract

Immunodominance limits the TCR diversity of specific antiviral CD8 T cell responses elicited by vaccination or infection. To prime multispecific T cell responses, we constructed DNA vaccines that coexpress chimeric, multidomain Ags (with CD8 T cell-defined epitopes of the hepatitis B virus (HBV) surface (S), core (C), and polymerase (Pol) proteins and/or the OVA Ag as stress protein-capturing fusion proteins. Priming of mono- or multispecific, HLA-A*0201- or K(b)-restricted CD8 T cell responses by these DNA vaccines differed. K(b)/OVA(257-264)- and K(b)/S(190-197)-specific CD8 T cell responses did not allow priming of a K(b)/C(93-100)-specific CD8 T cell response in mice immunized with multidomain vaccines. Tolerance to the S- Ag in transgenic Alb/HBs mice (that express large amounts of transgene-encoded S- Ag in the liver) facilitated priming of subdominant, K(b)/C(93-100)-specific CD8 T cell immunity by multidomain Ags. The "weak" (i.e., easily suppressed) K(b)/C(93-100)-specific CD8 T cell response was efficiently elicited by a HBV core Ag-encoding vector in 1.4HBV-S(mut) tg mice (that harbor a replicating HBV genome that produces HBV surface, core, and precore Ag in the liver). K(b)/C(93-100)-specific CD8 T cells accumulated in the liver of vaccinated 1.4HBV-S(mut) transgenic mice where they suppressed HBV replication. Subdominant epitopes in vaccines can hence prime specific CD8 T cell immunity in a tolerogenic milieu that delivers specific antiviral effects to HBV-expressing hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542448     DOI: 10.4049/jimmunol.0900505

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?

Authors:  Claus Lundegaard; Ole Lund; Morten Nielsen
Journal:  Expert Rev Vaccines       Date:  2012-01       Impact factor: 5.217

2.  CD8+ T-Cell Response-Associated Evolution of Hepatitis B Virus Core Protein and Disease Progress.

Authors:  George F Gao; Jingmin Zhao; Yu Zhang; Yan Wu; Mengmeng Deng; Dongping Xu; Xiaodong Li; Zhihui Xu; Jun Hu; Han Zhang; Kefang Liu; Yingze Zhao; Feng Gao; Shengli Bi; William J Liu; Songdong Meng
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

3.  PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.

Authors:  Brian T Rekoske; Heath A Smith; Brian M Olson; Brett B Maricque; Douglas G McNeel
Journal:  Cancer Immunol Res       Date:  2015-06-03       Impact factor: 11.151

4.  Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

5.  Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope.

Authors:  Tracy J Ruckwardt; Cindy Luongo; Allison M W Malloy; Jie Liu; Man Chen; Peter L Collins; Barney S Graham
Journal:  J Immunol       Date:  2010-09-10       Impact factor: 5.422

6.  DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

Authors:  Heath A Smith; Brian T Rekoske; Douglas G McNeel
Journal:  Vaccine       Date:  2014-01-31       Impact factor: 3.641

7.  Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques.

Authors:  Eduardo L V Silveira; Mark H Fogg; Rachel M Leskowitz; Hildegund C Ertl; Roger W Wiseman; David H O'Connor; Paul Lieberman; Fred Wang; Francois Villinger
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

8.  Praziquantel facilitates IFN-γ-producing CD8+ T cells (Tc1) and IL-17-producing CD8+ T cells (Tc17) responses to DNA vaccination in mice.

Authors:  Qiang Zou; Xin Yao; Jin Feng; Zhinan Yin; Richard Flavell; Yanxin Hu; Guoxing Zheng; Jin Jin; Youmin Kang; Bing Wu; Xiaoxuan Liang; Congcong Feng; Hu Liu; Weiyi Li; Xianzheng Wang; Yumei Wen; Bin Wang
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

9.  Subdominant/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite.

Authors:  Mariana R Dominguez; Eduardo L V Silveira; José Ronnie C de Vasconcelos; Bruna C G de Alencar; Alexandre V Machado; Oscar Bruna-Romero; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

Review 10.  Approaches to vaccines against Orientia tsutsugamushi.

Authors:  Gustavo Valbuena; David H Walker
Journal:  Front Cell Infect Microbiol       Date:  2013-01-04       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.